{"disease":{"id":"mucosal-melanoma-of-the-head-and-neck","name":"mucosal melanoma of the head and neck"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04318717","title":"Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02748564","title":"Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03220009","title":"Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}